D. Boral Capital Reiterates Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $31.00 target price on the stock.

Several other analysts have also commented on the stock. HC Wainwright reissued a “buy” rating and set a $19.00 price target on shares of NRx Pharmaceuticals in a research report on Monday, November 25th. Ascendiant Capital Markets raised their target price on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Finally, EF Hutton Acquisition Co. I raised NRx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 21st.

NRx Pharmaceuticals Price Performance

NASDAQ NRXP traded up $0.16 during midday trading on Monday, hitting $2.85. 1,361,625 shares of the company traded hands, compared to its average volume of 5,424,329. The company has a market cap of $34.47 million, a PE ratio of -1.33 and a beta of 1.25. NRx Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $7.33. The company’s 50-day simple moving average is $1.42 and its 200-day simple moving average is $1.75.

Insider Activity at NRx Pharmaceuticals

In other news, Chairman Jonathan C. Javitt bought 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The shares were purchased at an average cost of $1.17 per share, with a total value of $46,800.00. Following the transaction, the chairman now directly owns 84,634 shares in the company, valued at approximately $99,021.78. The trade was a 89.62 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 19.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Townsquare Capital LLC purchased a new stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned approximately 0.14% of NRx Pharmaceuticals at the end of the most recent quarter. 4.27% of the stock is currently owned by institutional investors and hedge funds.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.